<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05624554</url>
  </required_header>
  <id_info>
    <org_study_id>1026-008</org_study_id>
    <secondary_id>2022-500164-35-00</secondary_id>
    <secondary_id>MK-1026-008</secondary_id>
    <secondary_id>2021-006593-23</secondary_id>
    <nct_id>NCT05624554</nct_id>
  </id_info>
  <brief_title>A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)</brief_title>
  <official_title>A Phase 3, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Without TP53 Aberrations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of nemtabrutinib compared to&#xD;
      investigator's choice of fludarabine plus cyclophosphamide plus rituximab (FCR) or&#xD;
      bendamustine plus rituximab (BR) in participants with previously untreated CLL/SLL without&#xD;
      17p deletion and/or tumor protein (TP) 53 mutation. The primary hypothesis is that&#xD;
      nemtabrutinib is superior to FCR/BR with respect to progression-free survival (PFS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2023</start_date>
  <completion_date type="Anticipated">February 7, 2031</completion_date>
  <primary_completion_date type="Anticipated">May 7, 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 as Assessed by Blinded Independent Central Review (BICR)</measure>
    <time_frame>Up to approximately 49 months</time_frame>
    <description>PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. PD is evaluated per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria 2018 as assessed by blinded independent central review (BICR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 94 months</time_frame>
    <description>OS is defined as the time from randomization to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) per iwCLL Criteria 2018 as Assessed by BICR</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>ORR is defined as the percentage of participants with complete response (CR), complete response with an incomplete recovery of the participant's bone marrow (CRi), nodular partial response (nPR), or Partial response (PR), per iwCLL criteria 2018 as assessed by BICR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) per iwCLL Criteria 2018 as Assessed by BICR</measure>
    <time_frame>Up to approximately 94 months</time_frame>
    <description>For participants who demonstrate a CR, CRi, nPR, or PR per iwCLL criteria as assessed by BICR, DOR is defined as the time from the first documented evidence of CR, CRi, nPR, or PR that led to response until disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experience an Adverse Event (AE)</measure>
    <time_frame>Up to approximately 94 months</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinue Study Treatment Due to an AE</measure>
    <time_frame>Up to approximately 94 months</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Small Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Nemtabrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered daily via oral tablet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FCR or BR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Investigator's choice of fludarabine plus cyclophosphamide plus rituximab (FCR) OR bendamustine plus rituximab (BR). Participants will receive either rituximab or specified approved rituximab biosimilar.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nemtabrutinib</intervention_name>
    <description>65 mg administered orally daily until disease progression, unacceptable toxicity, or discontinuation criteria met</description>
    <arm_group_label>Nemtabrutinib</arm_group_label>
    <other_name>MK-1026</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>25 mg/m^2 administered via intravenous (IV) infusion on Days 1, 2, and 3 of each 28-day cycle up to 6 cycles</description>
    <arm_group_label>FCR or BR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>250 mg/m^2 administered via IV infusion on Days 1, 2, and 3 of each 28-day cycle up to 6 cycles</description>
    <arm_group_label>FCR or BR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Administered via IV infusion on Days 1 and 2 of each 28-day cycle up to 6 cycles. The first dose is given as 70 to 90 mg/m^2. Subsequent doses may be escalated up to 90 mg/m^2, if applicable and as per local guidelines</description>
    <arm_group_label>FCR or BR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m^2 (cycle 1) followed by 500 mg/m^2 for remaining cycles</description>
    <arm_group_label>FCR or BR</arm_group_label>
    <other_name>RITUXANÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Truxima</intervention_name>
    <description>Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m^2 (cycle 1) followed by 500 mg/m^2 for remaining cycles</description>
    <arm_group_label>FCR or BR</arm_group_label>
    <other_name>Rituximab biosimilar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ruxience</intervention_name>
    <description>Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m^2 (cycle 1) followed by 500 mg/m^2 for remaining cycles</description>
    <arm_group_label>FCR or BR</arm_group_label>
    <other_name>Rituximab biosimilar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Riabni</intervention_name>
    <description>Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m^2 (cycle 1) followed by 500 mg/m^2 for remaining cycles</description>
    <arm_group_label>FCR or BR</arm_group_label>
    <other_name>Rituximab biosimilar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        The main inclusion and exclusion criteria include but are not limited to the following:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma&#xD;
             (SLL) and active disease clearly documented to have a need to initiate therapy&#xD;
&#xD;
          -  Has previously untreated CLL/SLL participants without tumor protein 53 (TP53)&#xD;
             aberrations and documented 11q status and immunoglobulin heavy chain gene (IGHV)&#xD;
             mutational status&#xD;
&#xD;
          -  The ability to swallow and retain oral medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection&#xD;
&#xD;
          -  Gastrointestinal dysfunction that may affect drug absorption (eg, gastric bypass&#xD;
             surgery, gastrectomy)&#xD;
&#xD;
          -  Known additional malignancy that is progressing or has required active treatment&#xD;
             within the past 3 years, except basal cell carcinoma of skin, squamous cell carcinoma&#xD;
             of skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that&#xD;
             have undergone potential curative therapy&#xD;
&#xD;
          -  History of severe bleeding disorders&#xD;
&#xD;
          -  Not adequately recovered from major surgery or has ongoing surgical complications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aalborg Universitetshospital, Syd ( Site 1901)</name>
      <address>
        <city>Aalborg</city>
        <state>Nordjylland</state>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4597660000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital ( Site 2500)</name>
      <address>
        <city>Hksar</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+85222551654</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>FejÃ©r Megyei Szent GyÃ¶rgy Egyetemi OktatÃ³ KÃ³rhÃ¡z ( Site 2609)</name>
      <address>
        <city>SzÃ©kesfehÃ©rvÃ¡r</city>
        <state>Fejer</state>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>36305828330</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Markhot Ferenc Oktatokorhaz es Rendelointezet ( Site 2608)</name>
      <address>
        <city>Eger</city>
        <state>Heves</state>
        <zip>3300</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36203149331</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szabolcs-SzatmÃ¡r-Bereg Megyei KÃ³rhÃ¡zak Ã©s Egyetemi OktatÃ³kÃ³r-HaematolÃ³gia osztÃ¡ly ( Site 2602)</name>
      <address>
        <city>Nyiregyhaza</city>
        <state>Szabolcs-Szatmar-Bereg</state>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>42599700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika NowotworÃ³w UkÅadu ChÅonnego ( S</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>225462223</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne-Klinika Hematologii i Transplantologii ( Site 3702)</name>
      <address>
        <city>GdaÅsk</city>
        <state>Pomorskie</state>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48585844255</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zaklad Opieki Zdrowotnej MSWiA z Warmi-Oddzial Kliniczny Hematologii ( Site 37</name>
      <address>
        <city>Olsztyn</city>
        <state>Warminsko-mazurskie</state>
        <zip>10-228</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48895398756</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tan Tock Seng Hospital ( Site 4202)</name>
      <address>
        <city>Singapore</city>
        <state>Central Singapore</state>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+65 6359 6555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital ( Site 4704)</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886-2-23123456 ext.18563629</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mega Medipol-Hematology ( Site 4904)</name>
      <address>
        <city>Stanbul</city>
        <state>Istanbul</state>
        <zip>34214</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>905437870708</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ege Universitesi Hastanesi ( Site 4902)</name>
      <address>
        <city>Ä°zmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905325566128</phone>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://merckoncologyclinicaltrials.com</url>
    <description>Merck Oncology Clinical Trials Information</description>
  </link>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>November 14, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2022</study_first_posted>
  <last_update_submitted>May 5, 2023</last_update_submitted>
  <last_update_submitted_qc>May 5, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

